Oxygen Biotherapeutics Ships New Formulation of Dermacyte(TM) Oxygen Concentrate

DURHAM, N.C., April 22, 2010 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc.
(Nasdaq:OXBT) today announced that the company has begun shipping its newly
formulated Dermacyte(TM) Oxygen Concentrate to customers who pre-ordered this
revolutionary beauty and skin care product on-line. Beginning this week, there
is no longer a waiting period for order fulfillment and customers can select a
shipping time-frame such as 3-5 days, or 1-2 days. Shipping rates will vary
accordingly. Retail orders can be placed on the newly designed secure website at
www.BuyDermacyte.com.

"Preorder sales for Dermacyte Oxygen Concentrate are encouraging and many orders
are from repeat customers who purchased our product last fall during the market
testing phase," said Chris Stern, company chairman and CEO. "The product now
being shipped has an improved formulation and shows the new brand design and
packaging that future Dermacyte products will feature, most notably the eye
cream that we expect to introduce this summer."

Dermacyte Oxygen Concentrate is a scientifically designed, proprietary
concentrate designed to enhance oxygen delivery to skin. It is the first product
in a broad and diverse cosmetic line currently under development by the Oxygen
Biotherapeutics. It uses our patented Oxycyte Technology, scientifically
designed to enhance oxygen delivery to tissues, such as skin. Some potential
benefits of increased oxygenation to the skin include a decrease in the
appearance of fine lines, wrinkles and dryness.

Oxygen is essential for radiant, young-looking skin. It assists in the
production of collagen and elastin, as well as with skin repair and
regeneration. As we age, the body's ability to deliver oxygen to dermal tissue
deteriorates. A lack of oxygen at the cellular level can cause skin to age
prematurely, increasing the appearance of fine lines and age spots, making skin
look dry and dull. A boost in oxygen may enhance the overall appearance and feel
of your skin, leaving it smoother and healthier-looking.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that
efficiently deliver oxygen to tissues in the body. The company has developed a
proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid
ventilation product called Oxycyte(TM) that is being formulated for both
intravenous and topical delivery for conditions including but not limited to
traumatic brain injury, decompression sickness and topical wounds, as well as
for personal skin care. More information is available at www.oxybiomed.com.

The Oxygen Biotherapeutics, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7277

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company's judgment as of
the date of this release. These statements include those referring to the plans
for the expansion of the Dermacyte product line and the timing of the
introduction of those new products. Matters beyond the company's control could
lead to delays in the new product introductions and customer acceptance of these
new products. Furthermore, there can be no assurance that such plans will lead
to meaningful sales of Dermacyte or generate any revenue for the company. The
company disclaims any intent or obligation to update these forward-looking
statements beyond the date of this release. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.

CONTACT: Oxygen Biotherapeutics, Inc.
Ellen Corliss, Vice President,
Corporate Communications and Investor Relations
(919) 806-4405